Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Abbott, acetate, alemtuzumab, animal, antibody, approvedHorizant, argument, assigned, Avonex, Bayer, Betaseron, Biogen, cladribine, cohort, Copaxone, crossover, Daclizumab, deducting, dimethyl, Division, DMF, experimental, Extavia, fasted, fed, feedback, fingolimod, Foundation, Fox, Genzyme, Germany, Gilenya, glatiramer, healing, healthy, Heightened, Idec, idiopathic, injectable, Labour, Laquinimod, Lemtrada, metabolite, Michael, mixture, monthly, Movecto, natralizumab, nerve, neurodegeneration, OIG, opt, outbreak, Postemployment, Rebif, Serono, settlement, Teriflunomide, theHorizantFDA, toHorizantto, Tysabri, underwriting, underwritten, unfamiliarity, vacated, widely, zoster
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.37 Severance Rights Agreement
- 10.38 Xenoport Corporate Bonus Plan
- 31.1 Certification of the CEO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 31.2 Certification of the CFO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 32.1 Certification Required by Rule 13A-14(B) or Rule 15D-14(B) and Section 1350
Related press release
XNPT similar filings
Filing view
External links